Sponsored by
News Collaboration on Fleming Initiative to fight AMR
Diagnostic firm Cepheid has announced a new partnership with the Fleming Initiative, a global collaboration established by Imperial College Healthcare NHS Trust and Imperial College London to combat antimicrobial resistance (AMR). Cepheid is the first diagnostic company to pledge support towards the Fleming Initiative’s collaborative efforts for real-world solutions. The new partnership will be introduced at an event in New York aligned with the United Nations General Assembly High Level Meeting about AMR. The Fleming Initiative brings together research scientists, policymakers, clinicians, behavioural experts, public and commercial partners to provide the networks, expertise and skills to provide equitable solutions to AMR at the global scale. “Almost everyone who has visited a healthcare
provider for an undiagnosed infection has taken antibiotics as a preventative measure at one time in our lives. Too often, we are given broad spectrum antibiotics for viral infections or allergic reactions instead of as a treatment for a bacterial infection. That’s how antimicrobial resistance develops,” said Vitor Rocha, President of Cepheid. “Accurate diagnostics are at the frontline of the battle to eliminate preventative antibiotic use. Every one of us can help reduce unnecessary antibiotic use by requesting an accurate diagnostic test to identify the source of an infection before we begin a course of antibiotics.” The Initiative will draw on diverse expertise and public involvement to tackle antimicrobial resistance from all angles. The partners will work
together to catalyse worldwide action in the fight against AMR where poverty, climate change, and health inequality exacerbate the issues caused by drug-resistant infections. “At the Fleming Initiative we aim to unlock
powerful new ideas to drive significant change in the fight against AMR. This requires collective innovation across industries, from practitioners to policy makers and the public,” said Professor the Lord Darzi of Denham, Executive Chair of the Fleming Initiative. “I am delighted to welcome Cepheid as our first diagnostics partner. Currently 20% of antibiotic prescriptions given in primary care lack an appropriate diagnosis. We have to do better. Cepheid’s expertise will be essential to our efforts to ensure antibiotics work for generations to come.”
Cepheid’s significant pledge to the Fleming
Initiative will be used for collaborative scientific and clinical research, with a focus on strengthening and expanding the use of in vitro diagnostics to support antimicrobial stewardship programmes to enable responsible antibiotic use and control the rise of resistant infections. The collaboration will focus initially on the most critical areas of AMR: 1. Encourage active screening for carbapenemase-producing Enterobacteriaceae (CPE) for earlier detection of critical infections and colonisation
2. Implementation of community-based acute respiratory infection (ARI) testing and care pathways to provide decentralised diagnostic and treatment pathways
3. Accelerate a precision medicine approach for sepsis to identify and treat patients with a particular sepsis response state.
Mediplus TIVA Sets Dedicated infusion delivery systems
Designed in conjunction with anaesthetists to meet the highest TIVA standards as outlined in the guidelines*
Get in touch: +44 (0)1494 551200 @MediplusTIVA
marketing@mediplusuk.com
www.mediplusuk.com
*Nimmo AF, Absalom AR, Bagshaw O, et al. Guidelines for the safe practice of total intravenous anaesthesia (TIVA): joint guidelines from the Association of Anaesthetists and the Society for Intravenous Anaesthesia, 2018)
November 2024 I
www.clinicalservicesjournal.com 13
Nicolae -
stock.adobe.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
